Comment from IQVIA

Summary: IQVIA, a global provider of clinical research services and advanced analytics, expresses strong support for the FDA's proposed pilot program to evaluate AI-enabled technologies in early-phase clinical trials. The company argues that the pilot should focus on high-decision-density settings, prioritize critical foundational capabilities like safety monitoring and dose-escalation support, and establish a structured, risk-based pathway to generate durable regulatory guidance.